AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease ...

Columnist Caroline Gainer finds the mantra "Stay busy. Be useful." to be good guiding words for living with COPD.

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition, the ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in second-quarter profit, supported by continued strength in its HIV and oncology ...

Nucala stands out as the only approved biologic that has been specifically evaluated in patients whose eosinophilic phenotype is defined by a blood eosinophil count (BEC) threshold as low as ≥ ...

PHILADELPHIA - The US Food and Drug Administration has recently approved Nucala (mepolizumab) for use as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...

Patients were randomised 1:1 to receive Nucala 100mg or placebo subcutaneously every four weeks in addition to standard triple therapy for 52–104 weeks.

Nucala, a monoclonal antibody targeting interleukin-5 (IL-5), is already approved in China for several IL-5 mediated conditions, including severe eosinophilic asthma and as an add-on therapy for ...

If approved, Nucala could be the first approved biologic with monthly dosing for patients with COPD. Nucala is currently approved for use in the China across three IL-5 mediated conditions.